Finance

Lists
GUD:TSE
Knight Therapeutics Inc
10,68 CA$
-1,39%
(-0,15) 1D
13 қаз., 16:00:01 GMT-4  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for GUD...
Open
10,84 CA$
High
10,84 CA$
Low
10,65 CA$
Mkt. cap
1,05 млрд
Avg. vol.
81,79 мың
Volume
93,74 мың
P/E ratio
71,21
52-wk high
11,00 CA$
52-wk low
5,66 CA$
EPS
0,15 CA$
Beta
-0,07
Shares outstanding
98,23 млн
No. of employees
830
Open
10,84 CA$
High
10,84 CA$
Low
10,65 CA$
Mkt. cap
1,05 млрд
Avg. vol.
81,79 мың
Volume
93,74 мың
P/E ratio
71,21
52-wk high
11,00 CA$
52-wk low
5,66 CA$
EPS
0,15 CA$
Beta
-0,07
Shares outstanding
98,23 млн
No. of employees
830
News stories
From web sources and news partners
Profile
Knight Therapeutics Inc. is a Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. It is listed on the Toronto Stock Exchange, with a market capitalization of $1.02 billion as of August 2019. Wikipedia
About Knight Therapeutics Inc
CEO-
Employees830
Founded2014
HeadquartersМонреаль, Квебек, Канада
SectorPharmaceutical industry
Last report
2026 ж. 06 там.
Fiscal period
Q2 2026
-0,03 CA$ /
0,00%miss
Revenue / Est. (CAD)
144,21 млн / 128,90 млн
+11,88%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CAD
Loading Previous Earnings...
Revenue
Net income
All values in CAD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
121,55 млн
133,11 млн
148,44 млн
144,21 млн
Cost of goods sold
65,74 млн
68,38 млн
79,33 млн
74,60 млн
Cost of revenue
65,74 млн
68,38 млн
79,33 млн
74,60 млн
Research and development expenses
8,69 млн
9,22 млн
9,41 млн
10,56 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
31,02 млн
35,45 млн
34,45 млн
36,64 млн
Operating expense
55,16 млн
58,51 млн
58,53 млн
60,66 млн
Total operating expenses
120,90 млн
126,90 млн
137,86 млн
135,25 млн
Operating income
646,00 м.
6,21 млн
10,58 млн
8,96 млн
Other non operating income
-271,00 м.
329,00 м.
4,17 млн
-487,00 м.
EBT including unusual items
-1,92 млн
11,22 млн
14,18 млн
-2,10 млн
EBT excluding unusual items
2,24 млн
1,57 млн
15,50 млн
7,21 млн
Income tax expense
1,87 млн
2,37 млн
1,01 млн
1,26 млн
Effective tax rate
-97,76%
21,12%
7,14%
-59,82%
Other operating expenses
-
-
-
-
Net income
-3,79 млн
8,85 млн
13,17 млн
-3,36 млн
Net profit margin
-3,12%
6,65%
8,87%
-2,33%
Earnings per share
-0,02
0,10
0,14
-0,03
Interest and investment income
1,11 млн
1,22 млн
952,00 м.
901,00 м.
Interest expense
-2,37 млн
-3,92 млн
-2,64 млн
-2,12 млн
Net interest expenses
-1,26 млн
-2,70 млн
-1,69 млн
-1,22 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
18,41 млн
16,47 млн
26,77 млн
23,97 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары